Cost-effectiveness of pazopanib: an example of improved transparency and accessibility of industry-sponsored economic evaluations through publication in peer-reviewed journals
We congratulate Amdahl et al. on publishing their paper about the cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma (mrcc) in Canada. [...]
Saved in:
| Published in: | Current oncology (Toronto) Vol. 23; no. 4; pp. e327 - 329 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Canada
Multimed Inc
01-08-2016
|
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | We congratulate Amdahl et al. on publishing their paper about the cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma (mrcc) in Canada. [...] |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 1198-0052 1718-7729 1718-7729 |
| DOI: | 10.3747/co.22.2741 |